
|Articles|March 3, 2020
Managed Care Considerations for Navigating Biosimilar and HER2-Directed Therapies for the Treatment of HER2-Positive Breast Cancer
https://www.pharmacytimes.org/on-demand/managed-care-considerations-for-navigating-biosimilar-and-her2-directed-therapies-for-the-treatment-of-her2-positive-breast-cancer
Advertisement
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NIH Grant Terminations Disrupt 1 in 30 Clinical Trials, Impacting Over 74,000 Participants
2
Single-Tablet Bictegravir/Lenacapavir Effective After Treatment Switch
3
Chemoradiotherapy Improved Survival in Older Patients With Stage 2 NSCLC
4
Medicaid Pays for Half of All Pediatric Hospitalizations
5














































